“…The emergence of microfluidics technology presents an enormous opportunity to address many of the fundamental challenges in ECMO, due to the ability of microfluidics to fashion gas transfer membranes thinner than hollow fiber membrane oxygenators (HFMO), shallower blood channels, and potentially to better recapitulate the smooth and gentle manner in which blood flows through small vessels in the lung during the physiological gas transfer process [ 17 , 18 , 19 ]. Over the past decade, tremendous progress has been made by a number of groups in the development of microfluidic oxygenators, leveraging advances in computational designs, microfabrication techniques, and biomaterials technologies toward prototype devices that have been tested in vitro and in vivo in a large number of proof of concept studies [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ].…”